Nektar Therapeutics (NASDAQ:NKTR) Stock Passes Above Two Hundred Day Moving Average of $0.91

Shares of Nektar Therapeutics (NASDAQ:NKTRGet Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.91 and traded as high as $1.51. Nektar Therapeutics shares last traded at $1.41, with a volume of 1,908,442 shares.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NKTR. Jefferies Financial Group increased their price objective on shares of Nektar Therapeutics from $0.50 to $1.00 and gave the stock a “hold” rating in a report on Wednesday, March 6th. William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a research report on Tuesday, March 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.50.

Read Our Latest Report on Nektar Therapeutics

Nektar Therapeutics Trading Up 11.0 %

The stock’s 50-day moving average is $1.44 and its 200-day moving average is $0.91. The stock has a market cap of $259.47 million, a price-to-earnings ratio of -1.53 and a beta of 0.71.

Nektar Therapeutics (NASDAQ:NKTRGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03. Nektar Therapeutics had a negative net margin of 195.02% and a negative return on equity of 107.31%. The company had revenue of $21.64 million during the quarter, compared to the consensus estimate of $14.91 million. During the same quarter last year, the company earned ($0.25) earnings per share. On average, equities analysts predict that Nektar Therapeutics will post -0.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 16,650 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $1.75, for a total value of $29,137.50. Following the completion of the sale, the chief executive officer now owns 863,239 shares of the company’s stock, valued at $1,510,668.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Howard W. Robin sold 16,650 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $1.75, for a total transaction of $29,137.50. Following the completion of the sale, the chief executive officer now owns 863,239 shares of the company’s stock, valued at $1,510,668.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Deep Track Capital, Lp sold 56,000 shares of Nektar Therapeutics stock in a transaction on Friday, May 10th. The stock was sold at an average price of $1.78, for a total transaction of $99,680.00. Following the completion of the sale, the insider now owns 18,344,000 shares of the company’s stock, valued at approximately $32,652,320. The disclosure for this sale can be found here. Insiders sold 80,005 shares of company stock valued at $141,689 over the last 90 days. 3.71% of the stock is owned by corporate insiders.

Institutional Trading of Nektar Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new stake in shares of Nektar Therapeutics in the third quarter worth $11,138,000. Acadian Asset Management LLC increased its stake in shares of Nektar Therapeutics by 73.5% in the third quarter. Acadian Asset Management LLC now owns 7,626,388 shares of the biopharmaceutical company’s stock worth $4,540,000 after buying an additional 3,230,368 shares during the last quarter. Monaco Asset Management SAM increased its stake in shares of Nektar Therapeutics by 24.2% in the fourth quarter. Monaco Asset Management SAM now owns 5,973,387 shares of the biopharmaceutical company’s stock worth $3,375,000 after buying an additional 1,163,786 shares during the last quarter. GSA Capital Partners LLP increased its stake in shares of Nektar Therapeutics by 185.5% in the fourth quarter. GSA Capital Partners LLP now owns 5,255,790 shares of the biopharmaceutical company’s stock worth $2,970,000 after buying an additional 3,414,712 shares during the last quarter. Finally, Lynx1 Capital Management LP increased its stake in Nektar Therapeutics by 7.2% during the first quarter. Lynx1 Capital Management LP now owns 2,068,842 shares of the biopharmaceutical company’s stock valued at $1,933,000 after purchasing an additional 139,644 shares during the last quarter. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

See Also

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.